Cost-effectiveness of colorectal cancer screening - an overview.

[1]  J. Berthelot,et al.  Potential impact of population-based colorectal cancer screening in Canada. , 2003, Chronic diseases in Canada.

[2]  Amy B. Knudsen,et al.  Evaluating Test Strategies for Colorectal Cancer Screening: A Decision Analysis for the U.S. Preventive Services Task Force , 2008, Annals of Internal Medicine.

[3]  J. Ho,et al.  A sensitive guaiac faecal occult blood test is less useful than an immunochemical test for colorectal cancer screening in a Chinese population , 2003, Alimentary pharmacology & therapeutics.

[4]  Michael Pignone,et al.  Workshop Agenda: Economic Models of Colorectal Cancer Screening in Average-Risk Adults , 2005 .

[5]  H. Glick,et al.  Cost-effectiveness Analysis of Strategies for Colorectal Cancer Screening in Japan , 1994, International Journal of Technology Assessment in Health Care.

[6]  S. Goldie.  Public health policy and cost-effectiveness analysis , 2003 .

[7]  S. Moss,et al.  Population screening for colorectal cancer: the implications of an ageing population , 2008, British Journal of Cancer.

[8]  C. Hassan,et al.  Cost-effectiveness of capsule endoscopy in screening for colorectal cancer , 2008, Endoscopy.

[9]  Amy B. Knudsen,et al.  Cost-Effectiveness of DNA Stool Testing to Screen for Colorectal Cancer , 2007 .

[10]  D. Gyrd-Hansen,et al.  The relative economics of screening for colorectal cancer, breast cancer and cervical cancer. , 1999, Critical reviews in oncology/hematology.

[11]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[12]  BlueCross BlueShield.  Special report: critical appraisal of CT colonography cost-effectiveness analyses. , 2009, Technology Evaluation Center Assessment Program. Executive summary.

[13]  J. Habbema,et al.  Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. , 2009, Journal of the National Cancer Institute.

[14]  M. Leshno,et al.  Cost-Effectiveness of Colorectal Cancer Screening in the Average Risk Population , 2003, Health care management science.

[15]  S. Moss,et al.  Randomised controlled trial of faecal-occult-blood screening for colorectal cancer , 1989, The Lancet.

[16]  Wilson Jm,et al.  Principles and practice of mass screening for disease , 1968 .

[17]  J. Habbema,et al.  Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy , 2009, Gut.

[18]  J. Norum.  Prevention of colorectal cancer: a cost-effectiveness approach to a screening model employing sigmoidoscopy. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  Robert J. Mayer,et al.  Erratum: Colorectal cancer screening: Clinical guidelines and rationale (Gastroenterology (1997) 112 (594-642)) , 1997 .

[20]  S. Goldie.  Chapter 15: Public health policy and cost-effectiveness analysis. , 2003, Journal of the National Cancer Institute. Monographs.

[21]  H. Anton-Culver,et al.  Gender and race/ethnicity affect the cost-effectiveness of colorectal cancer screening. , 2006, Journal of the National Medical Association.

[22]  T. Vos,et al.  Colorectal cancer screening in Australia: An economic evaluation of a potential biennial screening program using faecal occult blood tests , 2004, Australian and New Zealand journal of public health.

[23]  Deborah Schrag,et al.  The price tag on progress--chemotherapy for colorectal cancer. , 2004, The New England journal of medicine.

[24]  E. Hanisch,et al.  Comparative evaluation of a new bedside faecal occult blood test in a prospective multicentre study , 2006, Alimentary pharmacology & therapeutics.

[25]  L. Boardman,et al.  Colorectal Cancer in African Americans , 2005, The American Journal of Gastroenterology.

[26]  Rongwei Fu,et al.  Screening for Colorectal Cancer: A Targeted, Updated Systematic Review for the U.S. Preventive Services Task Force , 2008, Annals of Internal Medicine.

[27]  C. Tournigand,et al.  Adjuvant therapy for stage II and III colorectal cancer. , 2007, Seminars in oncology.

[28]  C. Hassan,et al.  Colon cancer prevention in Italy: cost-effectiveness analysis with CT colonography and endoscopy. , 2007, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[29]  L M Schuman,et al.  Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. , 1993, The New England journal of medicine.

[30]  J. P. Tucker,et al.  Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. , 2007, Journal of the National Cancer Institute.

[31]  P. V. van Putten,et al.  The views of gastroenterologists about the role of nurse endoscopists, especially in colorectal cancer screening , 2009, Alimentary pharmacology & therapeutics.

[32]  P. Glasziou,et al.  Cost‐effectiveness analysis of screening by faecal occult blood testing for colorectal cancer in Australia , 1996, Australian and New Zealand journal of public health.

[33]  K. Stronks,et al.  Uptake of faecal occult blood test colorectal cancer screening by different ethnic groups in the Netherlands. , 2009, European journal of public health.

[34]  Jane Wardle,et al.  Wide variation in adenoma detection rates at screening flexible sigmoidoscopy. , 2004, Gastroenterology.

[35]  R. Leicester,et al.  Colonoscopy services in the United Kingdom. , 1999, Endoscopy.

[36]  C. O'Morain,et al.  Methods and Economic Considerations: Group 1 Report , 2004, Endoscopy.

[37]  M Johannesson,et al.  On the decision rules of cost-effectiveness analysis. , 1993, Journal of health economics.

[38]  T. Church,et al.  Variation in detection of adenomas and polyps by colonoscopy and change over time with a performance improvement program. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[39]  P. Rozen,et al.  Comparative screening with a sensitive guaiac and specific immunochemical occult blood test in an endoscopic study , 2000, Cancer.

[40]  J. Warwick,et al.  Cost-effectiveness analysis of colorectal cancer screening with stool DNA testing in intermediate-incidence countries , 2006, BMC Cancer.

[41]  Hermann Brenner,et al.  Cost-effectiveness of colonoscopy in screening for colorectal cancer. , 2002, Archives of internal medicine.

[42]  J. Faivre,et al.  Cost-effectiveness analysis of fecal occult blood screening for colorectal cancer , 2004, International Journal of Technology Assessment in Health Care.

[43]  D. Mark.  Visualizing cost-effectiveness analysis. , 2002, JAMA.

[44]  David K Whynes,et al.  Cost-Effectiveness of Screening for Colorectal Cancer: Evidence from the Nottingham Faecal Occult Blood Trial , 2004, Journal of medical screening.

[45]  W. Kalow,et al.  Pharmacogenetics and pharmacogenomics: origin, status, and the hope for personalized medicine , 2006, The Pharmacogenomics Journal.

[46]  A. Neville,et al.  Cost‐effectiveness of colorectal cancer screening: Comparison of community‐based flexible sigmoidoscopy with fecal occult blood testing and colonoscopy , 2004, Journal of gastroenterology and hepatology.

[47]  M. Hakama,et al.  Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017. , 1997, Acta oncologica.

[48]  B. Hollingsworth,et al.  Efficiency measurement of health care: a review of non‐parametric methods and applications , 1999, Health care management science.

[49]  Perry J Pickhardt,et al.  Computed tomographic colonography to screen for colorectal cancer, extracolonic cancer, and aortic aneurysm: model simulation with cost-effectiveness analysis. , 2008, Archives of internal medicine.

[50]  BlueCross BlueShield.  Special report: fecal DNA analysis for colon cancer screening. , 2006, Technology Evaluation Center Assessment Program. Executive summary.

[51]  A. Zauber,et al.  Will Test-Specific Adherence Predict the Best Colorectal Cancer Screening Strategy? , 2009 .

[52]  E. Feuer,et al.  Improvement in the Diagnostic Evaluation of a Positive Fecal Occult Blood Test in an Integrated Health Care Organization , 2008, Medical care.

[53]  Edward Giovannucci,et al.  Modifiable risk factors for colon cancer. , 2002, Gastroenterology clinics of North America.

[54]  S. Cole,et al.  Comparison of a brush‐sampling fecal immunochemical test for hemoglobin with a sensitive guaiac‐based fecal occult blood test in detection of colorectal neoplasia , 2006, Cancer.

[55]  S. Vernon,et al.  Participation in colorectal cancer screening: a review. , 1997, Journal of the National Cancer Institute.

[56]  F. Kabbinavar,et al.  Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  Y Kopelman,et al.  The colon - the latest terrain for capsule endoscopy. , 2007, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[58]  L. Guittet,et al.  Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population , 2006, Gut.

[59]  C. Masseria.  Colorectal cancer in Italy: a review of current national and regional practice on screening and treatment , 2009, The European Journal of Health Economics.

[60]  A. Adrain,et al.  A comparison of fecal occult-blood tests for colorectal-cancer screening. , 1996, The New England journal of medicine.

[61]  J. Dominitz,et al.  Fecal occult blood testing in a general medical clinic: comparison between guaiac-based and immunochemical-based tests. , 2003, The American journal of medicine.

[62]  Tze-Yun Leong,et al.  Cost-Effectiveness Analysis of Colorectal Cancer Screening Strategies in Singapore: A Dynamic Decision Analytic Approach , 2004, MedInfo.

[63]  S. Ciatto,et al.  Measuring interval cancers in population‐based screening using different assays of fecal occult blood testing: The district of Florence experience , 2001, International journal of cancer.

[64]  S. Ciatto,et al.  Immunochemical vs guaiac faecal occult blood tests in a population-based screening programme for colorectal cancer. , 1996, British Journal of Cancer.

[65]  C. Mulrow,et al.  Colorectal cancer screening: clinical guidelines and rationale. , 1997, Gastroenterology.

[66]  Geoffrey S. Ginsburg,et al.  The Personalized Medicine Coalition , 2005, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.

[67]  C. Lepage,et al.  Immunochemical faecal occult blood tests are superior to guaiac-based tests for the detection of colorectal neoplasms. , 2008, European journal of cancer.

[68]  P. Tappenden,et al.  Option appraisal of population-based colorectal cancer screening programmes in England , 2006, Gut.

[69]  B. Leggett,et al.  Guaiac versus immunochemical tests: faecal occult blood test screening for colorectal cancer in a rural community , 2005, Australian and New Zealand journal of public health.

[70]  Ann G Zauber,et al.  Individualizing colonoscopy screening by sex and race. , 2009, Gastrointestinal endoscopy.

[71]  K. Tran.  Capsule colonoscopy: PillCam Colon. , 2007, Issues in emerging health technologies.

[72]  J. M. Wilson,et al.  [Principles and practice of mass screening for disease]. , 1968, Boletin de la Oficina Sanitaria Panamericana. Pan American Sanitary Bureau.

[73]  R D Etzioni,et al.  Obtaining long-term disease specific costs of care: application to Medicare enrollees diagnosed with colorectal cancer. , 1999, Medical care.

[74]  B. Levin,et al.  Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. , 2008, Gastroenterology.

[75]  M. Weinstein.  How much are Americans willing to pay for a quality-adjusted life year? , 2008, Medical care.

[76]  Iris Lansdorp-Vogelaar,et al.  Cost-Effectiveness of CT Colonography to Screen for Colorectal Cancer , 2009 .

[77]  Angelo Zullo,et al.  Cost‐effectiveness of colorectal cancer screening with computed tomography colonography , 2007, Cancer.

[78]  Michael Pignone,et al.  Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force. , 2002, Annals of internal medicine.

[79]  A. Fendrick,et al.  As tests evolve and costs of cancer care rise: reappraising stool‐based screening for colorectal neoplasia , 2008, Alimentary pharmacology & therapeutics.

[80]  H. Anton-Culver,et al.  Racial and ethnic colorectal cancer patterns affect the cost-effectiveness of colorectal cancer screening in the United States. , 2001, Gastroenterology.

[81]  T. Chen,et al.  Cost-effectiveness analysis for determining optimal cut-off of immunochemical faecal occult blood test for population-based colorectal cancer screening (KCIS 16) , 2007, Journal of medical screening.

[82]  Perry J Pickhardt,et al.  The Cost-Effectiveness of CT Colonography in Screening for Colorectal Neoplasia , 2007, The American Journal of Gastroenterology.

[83]  V. Bouvier,et al.  Cost-effectiveness analysis of two strategies for mass screening for colorectal cancer in France. , 2004, Health economics.

[84]  J. Olsen,et al.  Randomised study of screening for colorectal cancer with faecal-occult-blood test , 1996, The Lancet.

[85]  L. Bisanti,et al.  Randomized trial of different screening strategies for colorectal cancer: patient response and detection rates. , 2005, Journal of the National Cancer Institute.

[86]  L. Seeff,et al.  Colorectal Cancer Test Use from the 2005 National Health Interview Survey , 2008, Cancer Epidemiology Biomarkers & Prevention.

[87]  D. Chung.  Stool DNA Testing and Colon Cancer Prevention: Another Step Forward , 2008, Annals of Internal Medicine.

[88]  S. Ng,et al.  Cost‐effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia , 2008 .

[89]  A. Verbeek,et al.  Comparison of Guaiac and Immunochemical Fecal Occult Blood ests for Colorectal Cancer in a Screening Population , 2022 .

[90]  Angela Mariotto,et al.  Cost of care for elderly cancer patients in the United States. , 2008, Journal of the National Cancer Institute.

[91]  H. Brenner,et al.  Cost-saving analysis of screening colonoscopy in Germany. , 2007, Zeitschrift fur Gastroenterologie.

[92]  Bernadette Mazurek Melnyk,et al.  Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. , 2008, Annals of internal medicine.